Valuing Benefits to Inform a Clinical Trial in Pharmacy Do Differences in Utility Measures at Baseline Affect the Effectiveness of the Intervention?
Michela Tinelli, Mandy Ryan, Christine Bond, Anthony Scott
Pharmacoeconomics | ADIS INT LTD | Published : 2013
Awarded by Chief Scientist Office
The authors would like to thank the medical statistician and senior lecturer Dr Lorna Aucott, University of Aberdeen, for her helpful comments and suggestions. The MEDMAN trial was funded by the Department of Health for England and Wales and managed by a collaboration of the National Pharmaceutical Association, the Royal Pharmaceutical Society of Great Britain, the Company Chemist Association and the Co-operative Pharmacy Technical Panel, led by the Pharmaceutical Services Negotiating Committee. The research in this paper was undertaken while the author M. Tinelli was undertaking a research fellowship jointly funded by the Economic and Social Research Council (ESRC) and the Medical Research Council (MRC). The Health Economics Research Unit (HERU), University of Aberdeen is funded by the Chief Scientist Office of the Scottish Government Health Directorate. The authors' work was independent of the funders.